Neftalí Guzmán

Dr. Neftalí Guzmán

Universidad Catolica de Temuco, Temuco, Araucanía, Chile
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PLPablo Letelier
Pablo Letelier
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
AHAlfonso Heriberto Hernández-Monsalves
Alfonso Heriberto Hernández-Monsalves
NGNeftalí Guzmán
Neftalí Guzmán
Jorge G. FaríasJorge G. Farías
Jorge G. Farías
Juan Carlos RoaJuan Carlos Roa
Juan Carlos Roa
Biliary tract cancers (BTCs) are a group of highly aggressive malignant tumors with a poor prognosis. The current diagnosis is based mainly on imaging and intraoperative exploration due to brush cytology havinga low sensitivity and the standard markers, such as carcinoembryonic antigen (CEA) and carbohydrate 19-9 (CA19-9), not having enough sensitivity nor specificity to be used in a differential diagnosis and early stage detection. Thus, better non-invasive methods that can distinguish between normal and pathological tissue are needed. MicroRNAs (miRNAs) are small, single-stranded non-coding RNA molecules of ~20–22 nucleotides that regulate relevant physiological mechanisms and can also be involved in carcinogenesis. Recent studies have demonstrated that miRNAs are detectable in multiple body fluids, showing great stability, either free or trapped in circulating microvesicles, such as exosomes. miRNAs are ideal biomarkers that may be used in screening and prognosis in biliary tract cancers, aiding also in the clinical decisions at different stages of cancer treatment. This review highlights the progress in the analysis of circulating miRNAs in serum, plasma and bile as potential diagnostic and prognostic markers of BTCs.

22 September 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
SAScarleth Aburto
Scarleth Aburto
MCMischka Cisterna
Mischka Cisterna
JAJaviera Acuña
Javiera Acuña
CRCamila Ruíz
Camila Ruíz
SVSharon Viscardi
Sharon Viscardi
NGNeftalí Guzmán
Neftalí Guzmán
SARS-CoV-2 infection is a global public health problem, causing significant morbidity and mortality. Evidence shows that obesity is a recognized risk factor for hospitalization, admission to critical care units, and the development of serious complications from COVID-19. This review analyzes the available epidemiological evidence that relates obesity to a higher risk of severity and mortality from COVID-19, examining the possible pathophysiological mechanisms that explain this phenomenon on a cellular and molecular level.

Verified
Journal Article
Open access
PDF file
PLPablo Letelier
Pablo Letelier
RSRolando Saldías
Rolando Saldías
Pia Loren ReyesPia Loren Reyes
Pia Loren Reyes
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
NGNeftalí Guzmán
Neftalí Guzmán
Exposure to atmospheric air pollution containing volatile organic compounds such as polycyclic aromatic hydrocarbons (PAHs) has been shown to be a risk factor in the induction of lung inflammation and the initiation and progression of lung cancer. MicroRNAs (miRNAs) are small single-stranded non-coding RNA molecules of ~20–22 nucleotides that regulate different physiological processes, and their altered expression is implicated in various pathophysiological conditions. Recent studies have shown that the regulation of gene expression of miRNAs can be affected in diseases associated with outdoor air pollution, meaning they could also be useful as biomarkers of exposure to environmental pollution. In this article, we review the published evidence on miRNAs in relation to exposure to PAH pollution and discuss the possible mechanisms that may link these compounds with the expression of miRNAs.

24 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AHAlfonso Heriberto Hernández-Monsalves
Alfonso Heriberto Hernández-Monsalves
PLPablo Letelier
Pablo Letelier
CMCamilo Morales
Camilo Morales
EMEduardo Rojas Maturana
Eduardo Rojas Maturana
MVMauricio Alejandro Sáez Venegas
Mauricio Alejandro Sáez Venegas
NGNeftalí Guzmán
Neftalí Guzmán
Background: Artificial intelligence tools can help improve the clinical management of patients with severe COVID-19. The aim of this study was to validate a machine learning model to predict admission to the Intensive Care Unit (ICU) in individuals with COVID-19. Methods: A total of 201 hospitalized patients with COVID-19 were included. Sociodemographic and clinical data as well as laboratory biomarker results were obtained from medical records and the clinical laboratory information system. Three machine learning models were generated, trained, and internally validated: logistic regression (LR), random forest (RF), and extreme gradient boosting (XGBoost). The models were evaluated for sensitivity (Sn), specificity (Sp), area under the curve (AUC), precision (P), SHapley Additive exPlanation (SHAP) values, and the clinical utility of predictive models using decision curve analysis (DCA). Results: The predictive model included the following variables: type 2 diabetes mellitus (T2DM), obesity, absolute neutrophil and basophil counts, the neutrophil-to-lymphocyte ratio (NLR), and D-dimer levels on the day of hospital admission. LR showed an Sn of 0.67, Sp of 0.65, AUC of 0.74, and P of 0.66. RF achieved an Sn of 0.87, Sp of 0.83, AUC of 0.96, and P of 0.85. XGBoost demonstrated an Sn of 0.87, Sp of 0.85, AUC of 0.95, and P of 0.86. Conclusions: Among the evaluated models, XGBoost showed robust predictive performance (Sn = 0.87, Sp = 0.85, AUC = 0.95, P = 0.86) and a favorable net clinical benefit in the decision curve analysis, confirming its suitability for predicting ICU admission in COVID-19 and aiding clinical decision-making.

1 April 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
NGNeftalí Guzmán
Neftalí Guzmán
GLGiovanni Larama
Giovanni Larama
AÁAndrés Ávila
Andrés Ávila
Luis SalazarLuis Salazar
Luis Salazar

1 January 2024 in Journal of Medical Biochemistry
Verified
Journal Article
Open access
PDF file
PLPablo Letelier
Pablo Letelier
HDHugo Delgado
Hugo Delgado
FGFelipe Garrido
Felipe Garrido
FQFrancisco Quiñones
Francisco Quiñones
MSMartín Andrés San
Martín Andrés San
NGNeftalí Guzmán
Neftalí Guzmán
Background: COVID-19 is still a global health issue, there is limited evidence in South America regarding laboratory biomarkers associated with severe disease. The objective of our study was to identify hematological and hemostatic changes associated with severe COVID-19. Methods: A total of 170 hospitalized patients with COVID19 were included in the study, defining their severity according to established criteria. Demographic, clinical, and laboratory (days 1, 3, 7, 15) data were obtained. We performed a statistical analysis, assuming significance with a value of p < 0.05. We analyzed the correlation between severity and biomarkers and established cut-off values for severe patients through ROC curves, estimating Odds Ratio associated with severe disease. Results: Day 1 was observed significant differences between moderate vs severe patients for leukocytes (WBC), Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and D-dimer, establishing cut-off points for each of them. The markers we found associated to risk of severe disease were WBC (OR=3.2396; p = 0.0003), NLR (OR=5.7084; p < 0.0001), PLR (OR=4.4094; p < 0.0001), Neutrophil (OR=4.1193; p < 0.0001), D-dimer (OR=2.7827; p = 0.0124). Conclusions: The results allow to establish basic laboratory biomarkers associated to severe disease, which could be used as prognostic markers.